IgE-mediated immune response to cashew allergens

The IgE-mediated immune response to cashew allergens is a Type I hypersensitivity reaction triggered by specific proteins in cashew nuts, primarily the major allergens Ana o 1, Ana o 2, and Ana o 3 (UniProt P81110, P81111, Q8H2B8). This biological process begins with sensitization, where the immune system produces allergen-specific IgE antibodies that bind to high-affinity FcεRI receptors on mast cells and basophils (PMID: 26022868). Upon subsequent exposure, the cashew allergens cross-link these IgE antibodies, inducing a signaling cascade that leads to the rapid release of inflammatory mediators such as histamine and leukotrienes (PMID: 30553710). These mediators cause the clinical symptoms of cashew allergy, which can range from localized hives to systemic anaphylaxis, a life-threatening emergency (StatPearls, Type I Hypersensitivity). Therapeutic management involves both acute treatment with epinephrine to counteract systemic effects and long-term strategies like Omalizumab, which sequesters IgE to prevent mast cell activation (FDA, 2024). Additionally, cashew-specific oral immunotherapy (OIT) is used to increase the reaction threshold by inducing immunological desensitization (PMID: 29351144). Monitoring this response often involves measuring specific IgE levels to Ana o 3, which is a highly predictive biomarker for severe cashew allergy (PMID: 30553710).

Other names

Cashew nut allergyType I hypersensitivity to cashewAnacardium occidentale allergyIgE-mediated cashew hypersensitivity

Neutralization of circulating IgE to prevent receptor binding, antagonism of histamine H1 receptors, and systemic adrenergic stimulation to reverse anaphylactic symptoms.